Can Leptin-Derived Sequence-Modified Nanoparticles Be Suitable Tools for Brain Delivery?
- 2 March 2012
- journal article
- Published by Taylor & Francis in Nanomedicine
- Vol. 7 (3) , 365-382
Abstract
In order to increase the knowledge on the use of nanoparticles (NPs) in brain targeting, this article describes the conjugation of the sequence 12-32 (g21) of leptin to poly-lactide-co-glycolide NPs. The capability of these modified NPs to reach the brain was evaluated in rats after intravenous administration. The g21 was linked on the surface of NPs labeled with tetramethylrhodamine by means of the Avidin-Biotin technology. The g21-labeled NPs were injected into the tail vein of rats and, after animal sacrifice, the brain localization was evaluated by confocal microscopy, fluorescence microscopy and electron microscopy. Studies to evaluate the biodistribution of the g21-modified NPs in comparison to the unmodified NPs were also carried out. Moreover, to confirm the absence of any anorectic effect of g21 linked on the surface of NPs, appropriate studies were used to assess the rats. After intravenous administration, the g21-modified NPs were able to cross the blood-brain barrier and to enter the brain parenchyma. The biodistribution studies of both unmodified and modified NPs pointed out an uptake at liver and spleen level, whereas only the g21-modified NPs showed brain localization. The food-intake experiments pointed out that the intravenous administration of g21 conjugated to the NP surface did not produce any anorectic effect in the rats. g21-modified NPs were able to cross the blood-brain barrier. These new modified NPs could be effectively considered as useful carrier systems for brain drug delivery.Keywords
This publication has 55 references indexed in Scilit:
- Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistributionJournal of Controlled Release, 2010
- Structure and function of the blood–brain barrierNeurobiology of Disease, 2010
- Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseasesNeurobiology of Disease, 2010
- Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neuronesJournal of Controlled Release, 2009
- Polymeric nanoparticles for the drug delivery to the central nervous systemExpert Opinion on Drug Delivery, 2008
- Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123Journal of Controlled Release, 2007
- Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing ratsJournal of Drug Targeting, 2006
- Peptide-derivatized biodegradable nanoparticles able to cross the blood–brain barrierJournal of Controlled Release, 2005
- Poly(lactic acid) nanoparticles labeled with biologically active Neutravidin™ for active targetingEuropean Journal of Pharmaceutics and Biopharmaceutics, 2004
- Brain drug delivery of small molecules using immunoliposomesProceedings of the National Academy of Sciences, 1996